Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

RCT (n=397 with severe Covid-19 not on mechanical ventilation) did not find significant difference between 5-and 10 course of remdesivir (clinical improvement ≥2 points in 64% and 54%, respectively), but magnitude of benefit could not be determined due to lack of placebo arm.

SPS commentary:

An editorial notes that in the current era of limited remdesivir supplies, priority should be given to a 5-day regimen for patients at the early stages of severe disease (i.e. on supplemental oxygen but have not yet been intubated), since the evidence for benefit is clearest in this population. It adds that as remdesivir supplies increase and more data accrue, understanding of the populations that will benefit most from remdesivir therapy may evolve further.


New England Journal of Medicine

Resource links: